drugset

drugset / Trial / NCT04825561

A Study to Evaluate the Efficacy and Safety of AD-208

NCT04825561 ↗

Phase 3 Completed 139 enrolled Addpharma Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-208.

Timeline

Start: 2021-06-09
Primary completion: 2023-01-09
Completion: 2023-06-01

Publications

Lee S, Kim JE, Lew BL, Huh CH, Kim J, Kwon O, Kim MB, Lee YW, Lee Y, Park J, Kim S, Kim DY, Choi GS, Kang H. Efficacy and Safety of Low-Dose (0.2 mg) Dutasteride for Male Androgenic Alopecia: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Trial. Ann Dermatol. 2025 Aug;37(4):183-190. doi: 10.5021/ad.25.048.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Dutasteride	Small molecule	0.2 mg	Oral
Comparator	Dutasteride	Small molecule	0.5 mg	Oral

Indications